Vivos Therapeutics’ Medical-Provider Model Shift Meets Persistent Profitability and Liquidity Challenges
The company’s pivot to acquiring and managing sleep medical practices aims to boost revenue but has yet to curb sizable operating losses.
Vivos Therapeutics, Inc. has evolved from a dentist-centric model toward vertical integration through acquisitions of sleep clinics and establishment of DSOs/MSOs, branded as Sleep and Airway Medicine Centers (SAMC). This strategic shift aims to enhance patient access and improve contribution margins by consolidating diagnostics, treatment, and administrative services. Despite these efforts, the company reported widening operating and net losses in 2025, negative operating cash flows, and a precarious liquidity position with a current ratio below 0.3. Capital raises remain essential for sustaining operations amid regulatory risks and litigation. Stakeholders will watch closely for evidence of scaling success and margin improvement to gauge the viability of this business model transition.
Overview: Business Model Evolution
Founded in 2016 with an initial go-to-market approach centered on training independent dentists (VIPs) to deploy proprietary oral appliance therapies for obstructive sleep apnea (OSA), Vivos Therapeutics developed The Vivos Method combining FDA-cleared devices like DNA and mRNA appliances with adjunctive therapies such as myofunctional therapy [S28]. By mid-2018, the VIP-centric model was dominant but evolved substantially in 2024 when Vivos shifted focus from independent dentists toward owning and managing sleep medical practices through Dental Service Organizations (DSOs) and Medical Service Organizations (MSOs). These are branded Sleep and Airway Medicine Centers (SAMC), designed as vertically integrated hubs offering comprehensive OSA diagnosis, treatment modalities, billing services, and administrative support [S28][S8].
This transformation reflects recognition that scaling treatment directly via medical providers – who can integrate diagnostics with device provision – offers the potential for larger patient volumes, improved case closure rates with Vivos therapies over CPAP reliance (which many patients abandon), higher top-line revenues per treated case ($5k), and improved contribution margins (50%) [S8][S14][S25].
Historical Financial Performance
Vivos has experienced an uneven financial trajectory marked by consistent operating losses exacerbated by its strategic pivots:
Historical performance (annual)
| FY | Net ($mm) | CFO ($mm) | OpInc ($mm) | Capex ($mm) | Net YoY |
|---|---|---|---|---|---|
| 2025 | -21 | -15 | -20 | 2 | -90.1% |
| 2024 | -11 | -13 | -11 | 1 | +18.0% |
| 2023 | -14 | -12 | -17 | 1 | +43.0% |
| 2022 | -24 | -20 | -25 | 1 |
Source: SEC companyfacts cache [F1].
Capital returns and efficiency (annual)
| FY | FCF ($mm) | ROE% |
|---|---|---|
| 2025 | -18 | 1420.8 |
| 2024 | -13 | -140.0 |
| 2023 | -13 | -3304.9 |
| 2022 | -21 | -496.7 |
Source: SEC companyfacts cache [F1].
Source: Company Annual Filings [F1], data compiled from fiscal year ends.
The company does not disclose revenue line items explicitly but reports increasing losses despite operational adjustments [F1]. Operating income declined by approximately 78% YoY from FY2024 to FY2025 while net loss widened by about 90%. Negative operating cash flow persisted at $15.3 million alongside rising capital expenditures reflecting investments in new clinical facilities such as the Auburn Hills Sleep Center commissioned in late 2025 [S8][F1]. The capex jump (+312%) between FY2024 and FY2025 corresponds primarily to infrastructure supporting SAMC expansion.
Shifting Growth Drivers: Medical Provider Integration
Vivos’ pivot seeks growth through:
- Broader Patient Access: Integrating sleep testing/treatment centers enables engagement with OSA candidates otherwise defaulting to CPAP therapy or untreated [S8].
- Higher Treatment Conversion: Pilot programs across multiple U.S. locations reported >70% patient uptake of Vivos oral appliance therapy when fully informed [S8].
- Enhanced Revenue Per Patient: Fee-for-service payments encompassing diagnostics, device provision, follow-up care coordinated under MSO/DSO management improve margins relative to independent dentist sales only [S14][S25].
- Multidisciplinary Provider Network: Expanding beyond dentists to include chiropractors, cardiologists, primary care physicians facilitates comprehensive respiratory health approaches catering to comorbid conditions [S28].
However, this growth path requires navigating complex corporate practice of medicine regulations restricting non-physician ownership/operation—adding compliance costs and risk exposure [S9][S15].
Legal & Regulatory Risks
Significant risks include:
- Corporate Practice of Medicine Compliance: Acquisitions must carefully structure ownership/trusts regarding licensed practitioners [S9][S15].
- Product Liability Exposure: Despite FDA clearances, inherent litigation risk exists related to injury or misuse claims from medical device marketing [S4][S6][S10]. Past FDA observations have been addressed but ongoing vigilance is necessary [S11].
- Healthcare Fraud & Abuse Laws: Medicare/Medicaid involvement triggers Anti-Kickback statutes, False Claims Act liabilities requiring robust compliance frameworks especially given provider relationships [S9][S17].
- Privacy & Data Security: HIPAA regulations govern protected health information involved in diagnostics/treatment centers imposing administrative burdens [S21].
- Litigation History & Settlements: A recent confidential settlement resolved trademark disputes limiting training/solicitation rights relating to certain pre-formed tooth positioners competitive with Ortho-Tain products impacting legacy dental-focused revenue models [S16].
Capital Structure & Liquidity Profile
As of December 31, 2025:
- Cash & equivalents: approximately $2 million,
- Current liabilities: approximately $18 million,
- Current ratio: ~0.24,
- Total equity: negative approximately -$1.49 million,
- Unsecured notes require weekly principal repayments,
- Fundraising includes at-the-market equity offerings capped near $5.8 million plus convertible/preferred instruments issued previously [F1][S13][S24].
Operating cash flows remain deeply negative (-$15.3 million), insufficient to cover capex ($2.34 million), leading to approximate free cash outflow exceeding $17 million in fiscal year 2025 alone [F1], underscoring ongoing dependence on external capital.
Outlook & Milestones To Monitor
No explicit financial guidance or profitability milestones have been provided; key indicators include:
- New Sleep and Airway Medicine Center openings,
- Patient volume growth within owned/managed centers,
- Case conversion ratios into Vivos Method treatments,
- Contribution margin trends demonstrating operational leverage,
- Regulatory audit outcomes including compliance with medical practice laws,
- Resolution status on product liability or regulatory investigations,
- Cash burn rate relative to capital raises.
Successful scaling paired with margin improvement is critical for shifting persistent losses toward sustainable cash generation given prior years’ deficits [F1].
Returns & Capital Allocation Policy
Due to ongoing losses, Vivos has not declared dividends or engaged materially in share buybacks per available data [F1][S29]. Return measures such as ROE are distorted by negative equity caused by accumulated deficits; approximate ROE exceeds +1400% due to this distortion but does not reflect profitable operations.
Capital allocation currently prioritizes maintaining liquidity for working capital needs rather than shareholder distributions.
Disclaimer: This analysis is based solely on publicly available filings and news reports as referenced; it does not constitute investment advice or recommendation.
Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.
Comments